(Q43140987)

14 November 2017

Recommended changes to oncology clinical trial design: revolution or evolution? (English)

1 reference

14 November 2017

1

Mark J Ratain

1 reference

14 November 2017

Rachel W Humphrey

2

1 reference

14 November 2017

Gary B Gordon

3

1 reference

14 November 2017

Gwen Fyfe

4

1 reference

14 November 2017

Peter C Adamson

5

1 reference

14 November 2017

Thomas R Fleming

6

1 reference

14 November 2017

Walter M Stadler

7

1 reference

14 November 2017

Donald A Berry

8

1 reference

14 November 2017

Carl C Peck

9

1 reference

14 November 2017

5 November 2007

1 reference

European Journal of Cancer

14 November 2017

1 reference

14 November 2017

44

1 reference

14 November 2017

8-11

1 reference

14 November 2017

1

1 reference

Rapamycin: something old, something new, sometimes borrowed and now renewed

14 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Model-based drug development

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Design issues of randomized phase II trials and a proposal for phase II screening trials

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

The ultimate model organism: progress in experimental medicine

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Can the pharmaceutical industry reduce attrition rates?

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Learning versus confirming in clinical drug development

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Some design issues in trials of microbicides for the prevention of HIV infection

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2673461

Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies?

15 August 2018

1 reference

12 December 2020

Randomized phase II clinical trials

1 reference

12 December 2020

Phase II oncology trials: let's be positive

1 reference

12 December 2020

Testing the wrong hypothesis in phase II oncology trials: there is a better alternative

1 reference

12 December 2020

Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties

1 reference

12 December 2020

Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration

1 reference

12 December 2020

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)

1 reference

12 December 2020

Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

1 reference

12 December 2020

10.1016/J.EJCA.2007.09.011

Identifiers

DOI

1 reference

release_yj6bmo6ucvcorawrnrqnyekbxa

14 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yj6bmo6ucvcorawrnrqnyekbxa

24 November 2022

mapped directly with Wikidata item

1 reference

14 November 2017

1 reference